Supernus Reports Rapid Response in Depression Drug SPN-820 Phase 2 Trials

SPN-820 is an innovative drug developed by Supernus Pharmaceuticals, designed as an intracellular modulator of mTORC1, aimed at treating major depressive disorder (MDD). In a phase 2a trial involving 40 adults, SPN-820 demonstrated rapid and substantial improvements in depressive symptoms, with reductions in scores on both the Hamilton Depression Rating Scale and Montgomery Åsberg Depression Rating Scale apparent within hours of dosing[1][2]. Notably, the drug was well-tolerated, with mild adverse events such as headache and nausea, and it showed a rapid-onset antidepressant response without dissociative side effects[2].